ReNeuron has extended cash runway as it focuses on validating its exosome platform
News release
by
ReNeuron Group PLC
London, UK
|
February 21, 2023 04:52 AM Eastern Standard Time
ReNeuron Group PLC executive chairman Iain Ross tells Proactive that the company is focused on generating in vivo data and validating its exosome delivery technology platform CustomEX as 2023 gets underway.
ReNeuron will conduct head-to-head studies with its competitors to produce the data needed to achieve the commercial validation of the platform, Ross said. The company's cash runway has also been extended into 2024 following a restructuring undertaken in 2022, he added.
Contact Details
Proactive UK Ltd
Proactive UK Ltd
+44 20 7989 0813
